| Popis: |
The aim of study was to evaluate the efficacy and tolerability of the the idarubicin, cytarabine (ara-C), and etoposide (ICE) remission induction protocol in comparison to the modified, risk-adjusted daunorubicin(DNR) and ara-C (DA) schedule. Fifty-six adults with primary acute myeloid leukemia (AML); median age 36 years, range 16-60 years, males 46%) were centrally randomized to receive one of the following two induction treatments: (a) ICE 7/10: idarubicin 10 mg/m2 per i.v. on days 1, 3, 5 ara-C 100 mg/m2 per day continuous infusion on days 1-7/10, etoposide 100 mg.m2 per day on days 1-5; (b) DA 3 + 7, high dose (HD) ara C: daunorubicin 60 mg/m2 per day i.v. on days 1, 2, 3 ara-C 100 mg/m2 per day continuous infusion on days 1-6 and then modified depending upon the day 6 bone marrow biopsy; in responders displaying >30% blast reduction and |
